Overview
- 9 inspections across 9 sites are on record.
- 16 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2018-05-04.
At a glance
Inspections
9
Sites
9
Observations
16
Career since
Jul 2014
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Alnylam Pharmaceuticals Inc. | 4 May 2018 | Human Drugs | View 483 → |
| Vertex Pharmaceuticals Incorporated | 7 Sep 2017 | Human Drugs | View 483 → |
| Simtra Deutschland GmbH | 27 Jun 2017 | Human Drugs | On file |
| Patheon Austria GmbH & CoKG | 2 Jun 2017 | Human Drugs | |
| Janssen Ortho LLC | 26 Feb 2016 | Human Drugs | On file |
Sites inspected
Alnylam Pharmaceuticals Inc.Cambridge, United States1 insp.
Vertex Pharmaceuticals IncorporatedBoston, United States1 insp.
Simtra Deutschland GmbHHalle (Westf.), Germany1 insp.
Patheon Austria GmbH & CoKGLinz, Austria1 insp.
Janssen Ortho LLCGurabo, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Sean R Marcsisin2 shared
Sharmista Chatterjee1 shared
Yong Hu1 shared
Kumar G Janoria1 shared
Zakaria I Ganiyu1 shared
Dennis Cantellops Paite1 shared
Arwa S El Hagrasy1 shared
Noreen Muniz1 shared
Sneha S Patel1 shared
Steven Fong1 shared
Full investigator report
Get the verbatim findings behind Christina A Capacci-Daniel's 16 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site